ANADYS ANNOUNCES EXPIRATION OF HART-SCOTT-RODINO

Anadys Pharmaceuticals, a biopharmaceutical company committed to the discovery, development and commercialization of novel anti-infective medicines, announced today the expiration of the waiting period under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act for the Company's exclusive global license and co-development agreement with Novartis. In conjunction with the HSR clearance, Anadys will receive the initial license payment of $20 million from Novartis.

PharmaLive (http://www.medadnews.com/News/Index.cfm?articleid=254243)